Helix BioPharma (TSX:HBP) LT-Debt-to-Total-Asset : 0.00 (As of Jan. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Helix BioPharma's long-term debt to total assests ratio for the quarter that ended in Jan. 2025 was 0.00.

Helix BioPharma's long-term debt to total assets ratio stayed the same from Jan. 2024 (0.00) to Jan. 2025 (0.00).

Helix BioPharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Helix BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma LT-Debt-to-Total-Asset Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.39

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Helix BioPharma LT-Debt-to-Total-Asset Calculation

Helix BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2024 is calculated as

LT Debt to Total Assets (A: Jul. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jul. 2024 )	/	Total Assets (A: Jul. 2024 )
	=	0	/	1.489
	=

Helix BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2025 is calculated as

LT Debt to Total Assets (Q: Jan. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2025 )	/	Total Assets (Q: Jan. 2025 )
	=	0	/	2.242
	=

Helix BioPharma (TSX:HBP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Helix BioPharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

HBP0:Germany

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.